Skip to content Skip to main menu

Smart Healthcare



Changing in vitro diagnostic trend: From invasive to noninvasive

Next generation sequencing (NGS) analysis makes it possible to analyze genomic information quickly and easily, enabling the detection of many previously unknown biomarkers. This expands the possibilities of in vitro diagnostic methods related to diagnostic treatment, precision medicine and molecular diagnostics. Most existing diagnostic methods such as biopsy are invasive, samples cannot be obtained before the onset of the disease, and other diseases can occur due to sequelae. Also, there is limited information available due to genetic heterogeneity in different parts of the same tumor or heterogeneity in metastasized tumors. However, a liquid biopsy using blood or urine is a non-invasive method that avoids the side effects of biopsy, is useful for periodically monitoring the patient's progress, and for early diagnosis of potential diseases that have not yet developed. Due to these advantages, liquid biopsy is attracting attention as a new in vitro diagnostic trend.

Innovation of extracellular vesicle biomarkers in blood and urine

While conventional microbiome analysis is limited to stool, it is now possible to analyze blood and urine through MD Healthcare’s microbial EV technology. By harnessing the microbiome genetic information contained in the EVs present in blood or urine, it is possible to predict the risk of a specific disease occuring, screening, and therapeutic response to drugs. In addition, through NGS analysis of blood and urine, various incurable diseases can be diagnosed simultaneously. Diagnosis based on microbial EV genetic information is a core in vitro diagnostic technology that represents the future of precision medicine.